Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | NOS1 | P29475 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | NOS2 | P35228 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31114379 | 1.00 | MAPT (0.58) | MAPTALDH1A1NOS1KDM4EMEN1 | |
| SCHEMBL760073 | 0.81 | TDP1 (0.52) | MAPTALDH1A1NOS1KDM4EMEN1 | |
| SCHEMBL13122675 | 0.80 | MAPT (0.55) | MAPTALDH1A1NOS1KDM4EMEN1 | |
| SCHEMBL30799435 | 0.80 | MAPT (0.50) | MAPTALDH1A1NOS1KDM4EMEN1 | |
| SCHEMBL3004143 | 0.80 | MAPT (0.50) | MAPTALDH1A1NOS1KDM4EMEN1 | |
| SCHEMBL30799054 | 0.80 | MAPT (0.50) | MAPTALDH1A1NOS1KDM4EMEN1 | |
| SCHEMBL27143397 | 0.80 | MAPT (0.50) | MAPTALDH1A1NOS1KDM4EMEN1 | |
| SCHEMBL3534877 | 0.78 | MAPT (0.48) | MAPTALDH1A1NOS1KDM4EMEN1 | |
| SCHEMBL11728097 | 0.76 | PARP1 (0.51) | MAPTALDH1A1NOS1KDM4EMEN1 | |
| SCHEMBL27174860 | 0.76 | MAPT (0.47) | MAPTALDH1A1NOS1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083844-A1 | DOWNREGULATING INOS TO INCREASE CAR-T KILLING | H LEE MOFFITT CANCER CT & RES (US) | 2026-03-26 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20250255850-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2025-08-14 | — | — | US | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| WO-2024224296-A2 | TARGETED PHARMACEUTICAL COMPOSITIONS TO TREAT NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-10-31 | — | — | WO | claimed |
| US-20240316006-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-09-26 | — | — | US | claimed |
| WO-2024059834-A2 | DOWNREGULATING INOS TO INCREASE CAR-T KILLING | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. (US) | 2024-03-21 | — | — | WO | claimed |
| CN-105543023-A | Solution for removing residue, method of removing the residue, and method for producing semiconductor device | DAIKIN IND LTD | 2016-05-04 | — | — | CN | claimed |
| US-8822396-B2 | Solution for removing residue after semiconductor dry process and method of removing the residue using the same | DAIKIN INDUSTRIES, LTD. (JP) | 2014-09-02 | — | — | US | claimed |
| CN-102839062-A | Application of residue-removing solution | DAIKIN IND LTD | 2012-12-26 | — | — | CN | claimed |
| WO-2005041894-A2 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, REVERSING AND INHIBITING PAIN | METAPHORE PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-20040220242-A1 | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | claimed |
| US-20040220113-A1 | Inhibitors of serine protease activity methods and compositions for treatment of nitric oxide-induced clinical conditions | BIO HOLDING, INC. | 2004-11-04 | — | — | US | claimed |
| US-20030022866-A1 | Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold | THE JOHNS HOPKINS UNIVERSITY | 2003-01-30 | — | — | US | claimed |
| US-6476007-B2 | Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold | THE JOHNS HOPKINS UNIVERSITY | 2002-11-05 | — | — | US | claimed |
| WO-2002069910-A2 | USE OF SUBSTANCES THAT PREVENT THAT THE NO SYNTHASE OF WARM-BLOODED ORGANISMS TAKES EFFECT, FOR PRODUCING COSMETIC OR DERMATOLOGICAL PREPARATIONS FOR THE TREATMENT AND/OR THE PROPHYLAXIS OF UNDESIRED SKIN PIGMENTATION | BEIERSDORF AG (DE) | 2002-09-12 | — | — | WO | claimed |
| US-20020081277-A1 | Methods and compositions for enhancing the immunostimulatory effect of interleukin-12 | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, NIH | 2002-06-27 | — | — | US | claimed |
| US-6375944-B1 | Methods and compositions for enhancing the immunostimulatory effect of interleukin-12 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2002-04-23 | — | — | US | claimed |
| US-20010031750-A1 | Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-10-18 | — | — | US | claimed |
| WO-2001041752-A2 | USE OF ISOFORM SPECIFIC INHIBITORS OF CGMP-DEPENDENT PROTEIN KINASE FOR TREATMENT OF PAIN | THE JOHNS HOPKINS UNIVERSITY (US) | 2001-06-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083844-A1 | DOWNREGULATING INOS TO INCREASE CAR-T KILLING | NOS2, NOS1, NOS3 | MAPT 2165/4885ALDH1A1 2338/4885NOS1 2/4885 |
| US-20240316006-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | NLN, ACHE, SMN1; SMN2 | MAPT 33/4885ALDH1A1 1646/4885NOS1 28/4885 |
| US-20250255850-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | NLN, ACHE, PYGB | MAPT 40/4885ALDH1A1 1254/4885NOS1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.